Lana Pine

The PETRA questionnaire proves valuable in assessing the transition readiness of juvenile idiopathic arthritis patients into adult care, with a focus on self-management skills.

The rheumatology month in review highlights fibromyalgia complexities, lupus advancements, and dietary links to gout for improved management.

BLA submission was based on data from phase 3 clinical trials in which DMB-3115 showed no clinically meaningful differences compared with the reference product for the treatment of plaque psoriasis.

The biosimilars month in review highlights interviews with experts discussing the cost-saving potential of increased biosimilars uptake in the US, a recent US Food and Drug Administration (FDA) approval, and the impact of a mandatory switch to an adalimumab biosimilar in New Zealand.

Efficacy, pharmacokinetics, immunogenicity, and safety were comparable between patients receiving the aflibercept biosimilar SB15 and the reference drug.

Various factors related to demographics, psychosocial behavior variables, and clinical characteristics were linked to health-related quality of life in patients with gout.

Among the fibromyalgia studies conducted in the US and Canada over the past 22 years, 90% of participants identified as White.

The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.

Stacie Bell, PhD, emphasizes the importance of collaborative or multidisciplinary care in patients with SLE.

Stacie Bell, PhD, highlights the lasting effects of childhood adversities in patients with pediatric lupus.

Stacie Bell, PhD, discusses the disagreement between adolescents and parents regarding how lupus impacts daily life.

Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials.

Results provide the first clinical evidence to suggest that afimetoran may offer a benefit to patients with cutaneous lupus erythematosus.

Maternal characteristics, sociodemographic factors, and paternal participation during the initial year of the TEDDY study were identified as key predictors of enhanced visit compliance in a pediatric cohort genetically predisposed to type 1 diabetes.

Results showed treatment with dipeptidyl peptidase-4 inhibitors (DPP-4i) improved bone mineral density and reduced osteoporosis risk in patients with type 2 diabetes.

Despite a boom of new, cost-efficient options for chronic conditions, prescriber and patient concern over clinical benefit persists.

Findings provide a theoretical framework for the early diagnosis and treatment of heart disease in patients with gout, especially for older individuals and those with hypertension.

Laura Donlin, PhD, highlights the significance of identifying new subtypes of rheumatoid arthritis, emphasizing the potential for a paradigm shift in RA treatment toward personalized care and early interventions.

Thyroid dysfunction was greater among patients with more severe CKD coupled with a high urine protein level.

Patients who reported almost daily fresh vegetable consumption had higher eGFR compared to those with occasional consumption and those who consumed salt-preserved vegetables.

Patients with gout who did not experience recurrent flares had a shorter mean time between diagnosis and the start of urate-lowering therapy compared with those who had ≥1 flare.

Patients with gout achieving target serum uric acid levels showed good adherence to urate-lowering therapy, used antihypertensive agents, and lacked a family history of gout.

Waist circumference and high lipid levels were associated with poor disease outcomes in gout, including flares and failure to achieve treatment target.

Patients with the highest Dietary Inflammatory Index have an increased risk of gout.

A higher prevalence of STI diagnosis is observed in adolescents and young adults with sickle cell disease compared with controls.

Although more than half of female patients with sickle cell disease reported sickle cell pain associated with their menstrual cycles, only 12.5% had used ≥1 hormonal therapies within the past 3 months.

The revised algorithm demonstrates 97% sensitivity in identifying pregnant patients with inherited bleeding disorders.

Peter C Taylor, PhD, discusses the efficacy and safety of nipocalimab in patients with active rheumatoid arthritis.

Peter C Taylor, PhD, discusses the current treatment landscape in rheumatoid arthritis and the unmet needs of this patient population.

The decision was based on both clinical and non-clinical data supporting the biosimilarity of bevacizumab-tnjn (Avzivi), previously named BAT1706.